Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

SCWorx (NASDAQ:WORX) Penny Stock: Why Shares Are Up 44% on a New Health System Contract

SCWorx (NASDAQ:WORX) shares traded up 44.40% to $3.87 after the company announced a new agreement with an independent, community-owned healthcare system serving New Mexico, Arizona, Colorado and Utah. Under the deal, SCWorx will provide healthcare supply chain data management services to improve the accuracy, …

Nitish Kishor | 20 October 2026

Tempus AI (NASDAQ:TEM) Says a Routine Pathology Slide Can Reveal Lung Cancer Biomarkers, and Shares Rise 7%

Tempus AI (NASDAQ:TEM) shares traded up 6.98% to $68.83 after the company announced results from a study of an AI-enabled pre-screening panel for advanced non-small cell lung cancer. The panel reached greater than 80% sensitivity across all 12 biomarkers assessed and above 90% for …

Nitish Kishor | 20 October 2026

Alvotech (NASDAQ: ALVO) Wins FDA Approval for Updated SIMLANDI Manufacturing Protocol, Doubling Adalimumab Biosimilar Batch Yields

The approved protocol update allows Alvotech (NASDAQ: ALVO) to extract significantly more drug substance from each production run of SIMLANDI, the company’s biosimilar referencing Humira (adalimumab), a widely used anti-inflammatory biologic historically prescribed for conditions including rheumatoid arthritis, psoriasis and inflammatory bowel disease. By …

Nitish Kishor | 20 October 2026

Clene (NASDAQ: CLNN) Files NDA Seeking Accelerated FDA Approval of CNM-Au8 for ALS Treatment Backed by Neurofilament Light Chain Biomarker Data

The filing leans on neurofilament light chain (NfL) data, a blood-based biomarker that reflects the degree of neuronal and axonal damage occurring in neurodegenerative disease. Regulators have increasingly accepted NfL as a surrogate marker capable of supporting accelerated-approval pathways in conditions such as ALS, …

Nitish Kishor | 20 October 2026

IceCure Medical (NASDAQ: ICCM) Begins Enrollment in FDA-Cleared ChoICE Post-Market Study of ProSense Cryoablation for Low-Risk Breast Cancer

ProSense is IceCure Medical’s (NASDAQ: ICCM) minimally invasive cryoablation system, which destroys targeted tissue using extreme cold rather than surgical excision, and has already received FDA clearance for use in appropriate low-risk breast cancer cases. The ChoICE study is structured as a post-market registry …

Nitish Kishor | 20 October 2026

Marker Therapeutics (NASDAQ: MRKR) Awarded $2.6 Million FDA Orphan Products Grant for MT-601 Phase 1 Pancreatic Cancer Trial

The FDA’s Orphan Products Development grant program funds clinical studies of products intended to treat rare diseases and conditions, and the award to Marker Therapeutics (NASDAQ: MRKR) will support the costs associated with advancing MT-601 into a dedicated Phase 1 study in pancreatic cancer, …

Nitish Kishor | 20 October 2026

Quoin Pharmaceuticals (NASDAQ: QNRX) Publishes Peer-Reviewed Netherton Syndrome Case Report Showing QRX003 Sustained Skin Clearance for 21 Months

Netherton syndrome is a rare autosomal recessive skin disorder caused by mutations in the SPINK5 gene, typically presenting with widespread skin inflammation, impaired skin barrier function, and chronic itching that can severely affect quality of life from early childhood. The published case, conducted under …

Nitish Kishor | 20 October 2026

Rapport Therapeutics (NASDAQ: RAPP) Phase 2 RAP-219 Bipolar Mania Trial Meets Primary and Secondary Endpoints With Positive YMRS and CGI-BP Data

The study enrolled 253 adults diagnosed with acute manic or mixed episodes associated with bipolar I disorder. By Week 3 of treatment, patients receiving RAP-219 showed a 3.1-point placebo-adjusted reduction on the Young Mania Rating Scale (YMRS), the standard clinician-rated measure of manic symptom …

Nitish Kishor | 20 October 2026

Vivos Therapeutics (NASDAQ: VVOS) Closes SOD Sciences Equity and Pseudohypoxia Test IP Deal to Expand Into Sleep Apnea and Chronic Disease Screening Market

Under the terms of the agreement, the convertible preferred stock issued as consideration carries potential dilution of up to 80 million shares of Vivos Therapeutics (NASDAQ: VVOS) common stock should the securities convert in full, tying the company’s near-term share count to the pace …

Nitish Kishor | 20 October 2026

QTREX Quantum (NASDAQ: QTREX) Regains Nasdaq Compliance After Meeting $1.00 Minimum Bid Price Requirement

Nasdaq’s Listing Rule 5550(a)(2) requires companies listed on certainNasdaqtiers to maintain a minimum closing bid price of $1.00 per share. Issuers that fall below that threshold for 30 consecutive trading days typically receive a compliance notice and a grace period to regain compliance, most …

Nitish Kishor | 20 October 2026
Support

Hi! How can we help you today?

Loading…